LQDALiquidia Corporation

$27.39+15% 1Y

$27.39

$21.8052 weeks$91.06

Is the price fair?

Good

Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 good, 2 without data

What the price assumes~+17% a yearderived · Jun 30, 2026

Priced for ~17% a year FCF growth. The price demands less than its three-year revenue growth of 194% a year, expectations look modest.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)middle of the market

FCF yieldbehind 83% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What LQDA's price assumes

Liquidia Corporation trades at 19.7× earnings against 19.7× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.

19.7

Trailing P/E · Drug Manufacturers - Specialty & Generic median 19.7 · 1.00× the median: the market pays up for this one

Price / sales: 17.3
Price / sales · as of 2026-Q2
Free cash flow yield: 2.2%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
Growth the price implies: +17%
Growth the price implies · The price pays for +17% free cash flow growth a year for a decade; revenue has grown +194% a year over the last three.